Categories: Posters and abstracts
Combination therapy of TERN-501, a selective agonist of thyroid hormone receptor (THR) beta with TERN-101, a farnesoid X receptor (FXR) agonist improves nonalcoholic steatohepatitis (NASH) in a GAN diet induced and biopsyconfirmed mouse model
European Association for the Study of the Liver (EASL) Liver Congress (2023)
Validation and utility of artificial intelligence-based zonal annotations as an additional assessment tool for the histopathologic review of fibrosis in non alcoholic steatohepatitis patients
European Association for the Study of the Liver (EASL) Liver Congress (2023)
Artificial intelligence assisted qFibrosis as a pathological “biomarker” to evaluate disease severity in patients with hepatocellular carcinoma
European Association for the Study of the Liver (EASL) Liver Congress (2023)
Artificial intelligence to measure fibrosis change on liver biopsy in MAESTRO-NASH a phase 3 52-week serial liver biopsy study in 966 patients with NASH treated with resmetirom or placebo
European Association for the Study of the Liver (EASL) Liver Congress (2023)
A deep exploration of bridging fibrosis evolution and individual septa parameters in NASH using quantitative second harmonic generation imaging reveals fibrosis changes in natural history and treatment-induced not seen with conventional histology
European Association for the Study of the Liver (EASL) Liver Congress (2023)
Quantification of vessel and bile duct parameters using Second Harmonic Generation in patients with NAFLD across fibrosis stages
European Association for the Study of the Liver (EASL) Liver Congress (2023)
Digital pathology using stain-free imaging indices as a tool for fibrosis quantification in patients with congestive hepatopathy
European Association for the Study of the Liver (EASL) Liver Congress (2023)
Artificial Intelligence analysis of liver biopsies in pre-cirrhotic NASH: qFibrosis explained
European Association for the Study of the Liver (EASL) Liver Congress (2023)
Repeatability and reproducibility assessment and its acceptable standard error of means for qFibrosis system in multi site NASH clinical trials
European Association for the Study of the Liver (EASL) Liver Congress (2023)